A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics
Journal of Neuromuscular Diseases · 2023
DOI: 10.3233/jnd-221636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, 2023. Verfasst von Amy E Campbell und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Hauptthemen laut MEDLINE: Homeodomain Proteins, Muscular Dystrophy, Facioscapulohumeral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Background
Facioscapulohumeral muscular dystrophy (FSHD) is a progressive myopathy caused by misexpression of the double homeobox 4 (DUX4) embryonic transcription factor in skeletal muscle. Identifying quantitative and minimally invasive FSHD biomarkers to report on DUX4 activity will significantly accelerate therapeutic development.
Objective
The goal of this study was to analyze secreted proteins known to be induced by DUX4 using the commercially available Olink Proteomics platform in order to identify potential blood-based molecular FSHD biomarkers.
Methods
We used high-throughput, multiplex immunoassays from Olink Proteomics to measure the levels of several known DUX4-induced genes in a cellular myoblast model of FSHD, in FSHD patient-derived myotube cell cultures, and in serum from individuals with FSHD. Levels of other proteins on the Olink Proteomics panels containing these DUX4 targets were also examined in secondary exploratory analysis.
Results
Placental alkaline phosphatase (ALPP) levels correlated with DUX4 expression in both cell-based FSHD systems but did not distinguish FSHD patient serum from unaffected controls.
Conclusions
ALPP, as measured with the Olink Proteomics platform, is not a promising FSHD serum biomarker candidate but could be utilized to evaluate DUX4 activity in discovery research efforts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- FSHD Society, Randolph, MA, USA.
- Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
- Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
- RNA Bioscience Initiative, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Förderung
- NICHD NIH HHS
- NIAMS NIH HHS
Zitieren
APA
Campbell, A. E., Arjomand, J., King, O. D., Tawil, R., & Jagannathan, S. (2023). A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics. Journal of Neuromuscular Diseases. https://doi.org/10.3233/jnd-221636
Vancouver
Campbell AE, Arjomand J, King OD, Tawil R, Jagannathan S. A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics. Journal of Neuromuscular Diseases. 2023. doi:10.3233/jnd-221636
BibTeX
@article{Campbell2023,
author = {Campbell, Amy E and Arjomand, Jamshid and King, Oliver D and Tawil, Rabi and Jagannathan, Sujatha},
title = {A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics},
journal = {Journal of Neuromuscular Diseases},
year = {2023},
doi = {10.3233/jnd-221636}
}
EUVIMED